Diffusion of interferon beta in Iran and its utilization in Tehran
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Epidemiology
Reference27 articles.
1. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines;Goodin;Neurology,2002
2. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis;Rotstein;Autoimmun Rev,2006
3. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents;Amato;Expert Opin Pharmacother,2004
4. Costs and quality of life of patients with multiple sclerosis in Europe;Kobelt;J. Neurol Neurosurg Psychiatry,2006
5. Multiple sclerosis: report on 200 cases from Iran;Kalanie;Mult Scler,2003
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison;Journal of Medical Economics;2018-11-20
2. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments;DARU Journal of Pharmaceutical Sciences;2013-06-22
3. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence;Health Policy;2011-05
4. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patients;Biomarkers in Medicine;2010-10
5. "We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran;Health Research Policy and Systems;2010-04-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3